guidelin
applic
immunocompet
pneumonia
cap
patient
age
year
older
immunocompromis
patient
human
immunodefici
viru
hiv
infect
agranulocytosi
haematolog
tumour
solid
tumour
undergo
solid
organ
transplant
patient
receiv
glucocorticoid
cytokin
antagonist
guidelin
may
inappropri
revis
guidelin
initi
chines
thorac
societi
ct
chines
medic
associ
cma
overal
framework
main
content
updat
guidelin
final
follow
work
meet
onlin
video
confer
expert
special
methodolog
provid
train
standard
literatur
search
grade
evid
specialist
contribut
guidelin
level
evid
grade
recommend
base
infecti
diseas
societi
americaamerican
thorac
societi
idsaat
guidelin
cap
level
evid
repres
assess
qualiti
studi
evid
grade
recommend
refer
assess
degre
benefit
intervent
outweigh
risk
gener
speak
higher
evid
level
stronger
grade
recommend
fulli
correspond
willing
valu
patient
well
resourc
consumpt
also
consid
make
recommend
tabl
guidelin
document
compos
section
core
panel
member
respons
separ
group
prepar
first
draft
search
review
relev
domest
intern
literatur
evalu
evid
level
unifi
standard
grade
recommend
decid
vote
member
particip
prepar
guidelin
princip
writer
respons
summar
modif
first
draft
process
work
meet
held
discuss
revis
draft
three
round
consult
conduct
solicit
advic
opinion
specialist
specialti
group
within
ct
cma
specialist
relev
disciplin
infecti
diseas
clinic
microbiolog
emerg
critic
care
medicin
clinic
pharmaci
specialist
unit
state
europ
guidelin
document
modifi
time
base
discuss
feedback
final
revis
version
approv
writer
consult
cap
refer
infecti
inflamm
lung
parenchyma
includ
alveolar
wall
ie
pulmonari
interstitium
gener
mean
acquir
outsid
hospit
includ
pneumonia
caus
pathogen
proven
latenc
onset
diseas
latenc
patient
admit
hospit
incid
cap
adult
european
north
american
increas
age
unit
state
averag
incid
cap
adult
inpati
popul
age
highest
popul
least
year
japanes
studi
show
incid
cap
popul
age
china
proport
cap
age
group
avail
present
time
specif
data
avail
incid
cap
adult
studi
conduct
china
show
hospit
cap
patient
much
larger
proport
found
year
year
age
group
compar
adult
year
age
mortal
cap
increas
age
patient
japan
report
mortal
hospit
cap
patient
year
age
group
year
age
group
year
age
group
year
age
cap
mortal
also
associ
sever
diseas
data
german
cap
surveil
network
show
mortal
cap
adult
patient
mortal
rate
outpati
inpati
addit
result
sever
studi
shown
mortal
cap
patient
current
lack
data
regard
incid
mortal
cap
china
accord
data
china
health
famili
plan
statist
yearbook
preval
pneumonia
china
slight
increas
compar
data
averag
mortal
pneumonia
china
specif
popul
popul
age
popul
age
popul
age
distribut
antimicrobi
resist
profil
cap
pathogen
significantli
differ
across
differ
countri
region
chang
time
current
result
sever
epidemiolog
survey
cap
conduct
chines
adult
shown
mycoplasma
pneumonia
streptococcu
pneumonia
import
pathogen
cap
adult
common
pathogen
includ
haemophilu
influenza
chlamydia
pneumonia
klebsiella
pneumonia
staphylococcu
aureu
pseudomona
aeruginosa
acinetobact
baumannii
infrequ
china
small
number
case
aureu
pneumonia
report
children
identifi
antimicrobi
resist
surveil
respiratori
tract
pathogen
adult
conduct
special
popul
elderli
patient
patient
underli
diseas
eg
congest
heart
failur
cardiovascular
cerebrovascular
diseas
chronic
respiratori
system
diseas
kidney
failur
diabet
mellitu
bacteria
k
pneumonia
escherichia
coli
develop
applic
viru
detect
technolog
role
respiratori
tract
virus
gradual
gain
attent
aetiolog
cap
chines
adult
result
sever
recent
publish
multicent
studi
show
detect
rate
virus
chines
adult
cap
patient
influenza
viru
account
largest
proport
contribut
virus
includ
parainfluenza
viru
rhinoviru
adenoviru
human
metapneumoviru
hmpv
respiratori
syncyti
viru
rsv
among
patient
posit
test
result
virus
could
concomit
infect
caus
bacteria
atyp
consid
resist
profil
major
pathogen
high
percentag
pneumonia
resist
macrolid
found
chines
adult
cap
patient
import
characterist
differ
european
american
countri
two
multicent
survey
adult
cap
conduct
show
pneumonia
isol
resist
recent
result
multicent
respiratori
tract
infect
pathogen
surveil
cartip
studi
adult
conduct
urban
tertiari
hospit
china
show
pneumonia
isol
resist
azithromycin
minimum
inhibitori
concentr
requir
inhibit
growth
organ
mgl
isol
resist
european
american
countri
pneumonia
isol
resist
erythromycin
azithromycin
moreov
pneumonia
isol
resist
oral
penicillin
resist
cephalosporin
china
howev
rel
low
percentag
pneumonia
isol
resist
inject
penicillin
cephalosporin
respect
high
percentag
mycoplasma
pneumonia
strain
resist
macrolid
anoth
import
characterist
aetiolog
cap
china
differ
countri
studi
result
show
mycoplasma
strain
isol
chines
adult
cap
patient
resist
erythromycin
resist
infect
caus
mycoplasma
may
prolong
durat
fever
addit
china
mycoplasma
strain
isol
japanes
adult
teenag
cap
patient
resist
macrolid
pneumonia
also
report
franc
canada
unit
state
spain
pneumonia
highli
resist
macrolid
china
remain
suscept
doxycyclin
minocyclin
onset
communityrelev
clinic
manifest
pneumonia
new
onset
cough
expector
aggrav
exist
symptom
respiratori
tract
diseas
without
purul
sputum
chest
pain
dyspnea
hemoptysi
fever
sign
pulmonari
consolid
andor
moist
rale
peripher
white
blood
cell
count
wbc
without
left
shiftchest
radiograph
show
new
patchi
infiltr
lobar
segment
consolid
opac
interstiti
chang
without
pleural
effus
clinic
diagnosi
establish
patient
satisfi
criterion
criterion
c
one
condit
criterion
b
meanwhil
tuberculosi
pulmonari
tumour
interstiti
lung
diseas
pulmonari
edema
atelectasi
pulmonari
embol
pulmonari
eosinophilia
pulmonari
vascul
exclud
step
determin
whether
diagnosi
cap
valid
patient
clinic
suspect
cap
possibl
unusu
infect
tuberculosi
caus
must
consid
step
evalu
sever
cap
select
locat
treatment
step
predict
potenti
pathogen
cap
risk
antibiot
resist
tabl
consid
patient
age
season
onset
underli
diseas
risk
factor
symptom
sign
characterist
chest
imag
film
ct
laboratori
test
sever
cap
prior
antibacteri
therapi
step
arrang
reason
etiolog
test
initi
empir
treatment
time
manner
step
evalu
effect
empir
treatment
cap
dynam
manner
investig
caus
initi
treatment
fail
adjust
treatment
protocol
promptli
step
follow
treatment
provid
educ
health
mainten
score
system
cap
sever
differ
tabl
use
aid
evalu
provid
support
clinic
diagnosi
treatment
physician
take
clinic
experi
consider
make
judgment
monitor
diseas
progress
dynam
ii
c
disturb
conscious
u
urea
nitrogen
r
respiratori
rate
b
blood
pressur
age
pneumonia
sever
index
psi
score
system
underestim
risk
death
sever
influenza
oxygen
index
combin
absolut
reduct
peripher
blood
lymphocyt
superior
psi
predict
risk
death
due
influenza
ii
b
score
recommend
standard
decid
whether
patient
hospit
score
point
theoret
patient
receiv
outpati
treatment
score
point
patient
recommend
receiv
inpati
treatment
extramur
treatment
close
score
point
patient
hospit
howev
factor
patient
age
underli
diseas
socioeconom
statu
gastrointestin
function
treatment
complianc
also
taken
account
comprehens
ii
b
requir
tracheal
intub
mechan
ventil
septic
shock
still
need
vasoact
drug
activ
fluid
resuscit
respiratori
rate
rr
bpm
oxygen
index
mm
hg
mm
hg
kpa
infiltr
multipl
lung
lobe
disturb
conscious
disorient
blood
urea
nitrogen
bun
mmoll
systol
blood
pressur
sbp
mm
hg
requir
activ
fluid
resuscit
unless
cluster
outbreak
pneumonia
clinic
respons
initi
empir
treatment
inadequ
etiolog
test
gener
requir
outpati
mild
iii
b
hospit
cap
patient
includ
patient
requir
monitor
emerg
room
usual
requir
etiolog
test
select
etiolog
test
base
multipl
factor
includ
patient
age
underli
diseas
immun
statu
clinic
characterist
sever
diseas
prior
treatment
appropri
etiolog
test
especi
import
antimicrobi
adjust
necessari
due
insuffici
efficaci
empir
see
tabl
recommend
etiolog
test
cap
specif
clinic
situat
invas
etiolog
sampl
select
applic
follow
patient
patient
pneumonia
concomit
pleural
effus
especi
pleural
effus
side
infect
pulmonari
lesion
etiolog
test
could
perform
pleural
effus
sampl
collect
via
thoracentesispati
receiv
mechan
ventil
etiolog
test
could
perform
lower
respiratori
tract
sampl
obtain
via
bronchoscopi
includ
endotrach
aspir
eta
bronchoalveolar
lavag
fluid
balf
protect
specimen
brush
psb
patient
inadequ
respons
empir
treatment
suspect
infect
unusu
pathogen
caus
diseas
determin
respiratori
tract
sampl
obtain
regular
method
etiolog
test
could
perform
lower
respiratori
tract
sampl
obtain
via
bronchoscopi
includ
eta
balf
psb
histolog
sampl
obtain
via
percutan
needl
lung
biopsypati
without
improv
activ
therapi
requir
differenti
diagnosi
pulmonari
lesion
tumour
vascul
interstiti
lung
diseas
iii
b
see
tabl
primari
test
method
cap
pathogen
correspond
diagnost
criteria
clinic
diagnosi
cap
establish
etiolog
test
sampl
arrang
appropri
potenti
pathogen
assess
term
patient
age
underli
diseas
clinic
characterist
result
laboratori
radiographi
test
sever
diseas
hepat
renal
function
histori
medic
antimicrobi
suscept
profil
evalu
risk
antibiot
resist
select
appropri
agent
dose
regimen
tabl
initi
empir
antibacteri
therapi
administ
promptli
import
note
epidemiolog
distribut
antimicrobi
resist
profil
pathogen
may
differ
differ
region
china
drug
list
tabl
option
initi
empir
therapi
treatment
recommend
theoret
select
therapi
specif
patient
must
base
actual
situat
local
healthcar
facil
addit
pharmacokinet
pharmacodynam
properti
antibacteri
agent
must
taken
consider
antibacteri
agent
penicillin
cephalosporin
monobactam
carbapenem
bactericid
abil
almost
satur
time
mic
time
mic
import
determin
better
clinic
efficaci
achiev
multipl
dose
per
day
base
meanwhil
bactericid
abil
antibacteri
agent
aminoglycosid
quinolon
increas
drug
concentr
effect
improv
higher
peak
drug
therefor
drug
usual
administ
daili
order
increas
drug
activ
decreas
risk
drug
resist
kidney
injuri
caus
aminoglycosid
recommend
guidelin
empir
treatment
cap
provid
follow
first
dose
agent
use
earli
possibl
diagnosi
cap
establish
order
improv
efficaci
decreas
mortal
hospit
stay
howev
import
note
correct
diagnosi
prerequisit
physician
ignor
necessari
differenti
diagnosi
purpos
earli
ii
b
mild
cap
outpati
oral
agent
high
bioavail
use
possibl
oral
treatment
amoxicillin
acid
b
young
patient
without
underli
diseas
oral
doxycyclin
minocyclin
may
consid
suspect
mycoplasma
chlamydia
iii
b
pneumonia
pneumonia
highli
resist
macrolid
empir
macrolid
treatment
use
region
lower
resist
ii
b
respiratori
quinolon
use
instead
region
higher
resist
rate
macrolid
patient
hypersensit
intoler
drug
mention
ii
b
cap
patient
requir
hospit
monotherapi
combin
doxycyclin
minocyclin
macrolid
respiratori
quinolon
monotherapi
ii
b
howev
compar
combin
therapi
respiratori
quinolon
monotherapi
associ
fewer
advers
skin
test
requiredfor
young
adult
patient
sever
cap
without
underli
diseas
requir
admiss
icu
inhibitor
combin
third
gener
cephalosporin
ertapenem
combin
macrolid
respiratori
quinolon
monotherapi
elderli
patient
patient
underli
diseas
combin
antimicrobi
therapi
ii
b
cap
patient
risk
aspir
optim
select
drug
activ
acid
moxifloxacin
carbapenem
therapi
combin
metronidazol
clindamycin
ii
hospit
patient
year
age
underli
diseas
eg
congest
heart
failur
cardiovascular
cerebrovascular
diseas
chronic
respiratori
system
diseas
kidney
failur
diabet
mellitu
etc
possibl
enterobacteriacea
infect
patient
evalu
risk
infect
esbl
bacteria
eg
histori
colon
infect
bacteria
prior
use
third
gener
cephalosporin
histori
repeat
hospit
indwel
implant
renal
replac
therapi
ertapenem
use
empir
therapi
patient
iii
b
influenza
season
cap
patient
suspect
influenza
viru
infect
recommend
receiv
regular
influenza
viru
antigen
test
nucleic
acid
assay
proactiv
antivir
therapi
neuraminidas
inhibitor
administ
simultan
even
h
diseas
onset
necessari
wait
result
influenza
pathogen
influenza
season
physician
must
awar
possibl
secondari
bacteri
infect
especi
pneumonia
aureu
h
influenza
rel
ii
therapi
usual
termin
day
fever
reliev
primari
respiratori
tract
symptom
improv
significantli
howev
durat
therapi
differ
base
sever
diseas
treatment
respons
complic
pathogen
necessari
use
chest
ct
indic
termin
agent
gener
durat
therapi
day
patient
mild
moder
cap
could
reason
prolong
patient
sever
cap
complic
durat
therapi
prolong
day
patient
atyp
pathogen
andor
slow
respons
treatment
aureu
p
aeruginosa
klebsiella
anaerob
bacteria
may
caus
necrosi
lung
tissu
therefor
durat
therapi
may
prolong
b
aetiolog
cap
determin
target
therapi
deliv
accord
result
vitro
suscept
test
see
tabl
common
pathogen
cap
common
agent
well
dosag
administr
blood
oxygen
level
hospit
cap
patient
evalu
time
manner
oxygen
therapi
via
nasal
cathet
face
mask
recommend
patient
hypoxemia
order
maintain
blood
oxygen
satur
addit
patient
risk
hypercapnia
oxygen
satur
maintain
obtain
result
blood
ga
iii
result
recent
studi
show
heat
humidifi
oxygen
therapi
via
nasal
cathet
lmin
could
also
use
clinic
ii
b
compar
oxygen
therapi
ventil
niv
includ
bilevel
posit
airway
pressur
continu
posit
pressur
ventil
decreas
endotrach
intub
rate
mortal
cap
patient
acut
respiratori
improv
oxygen
index
faster
decreas
incid
multipl
organ
septic
benefit
signific
patient
concomit
chronic
obstruct
pulmonari
ii
b
howev
cap
patient
acut
respiratori
distress
syndrom
ard
niv
shown
high
failur
improv
niv
also
appropri
cap
patient
sever
hypoxemia
oxygen
index
mm
hg
ii
addit
failur
niv
must
recogn
time
niv
failur
indic
niv
improv
respiratori
rate
oxygen
state
within
initi
therapi
decreas
blood
carbon
dioxid
level
patient
initi
oxygen
therapi
switch
tracheal
intub
ventil
immedi
ii
mechan
ventil
low
tidal
volum
mlkg
ideal
bodi
weight
use
cap
patient
ard
tracheal
patient
sever
cap
concomit
ard
extracorpor
membran
oxygen
ecmo
use
regular
mechan
ventil
lead
ii
b
indic
ecmo
includ
revers
respiratori
failur
associ
sever
hypoxemia
oxygen
index
mm
hg
hypoxemia
correct
even
h
posit
pressur
peep
seriou
decompensatori
acidosi
ph
excess
high
plateau
pressur
eg
cm
glucocorticoid
decreas
mortal
cap
patient
complic
septic
hydrocortison
succin
mgday
suggest
base
treatment
septic
drug
stop
promptli
septic
shock
correct
durat
therapi
normal
day
ii
c
benefit
glucocorticoid
unclear
sever
cap
patient
without
septic
shock
addit
system
use
glucocorticoid
caus
initi
therapi
assess
effect
failur
base
patient
respons
treatment
subsequ
manag
provid
accordingli
assess
initi
therapi
includ
follow
aspect
clinic
manifest
includ
respiratori
system
symptom
sign
iii
vital
sign
gener
condit
conscious
bodi
temperatur
respiratori
rate
heart
rate
blood
pressur
gener
laboratori
test
includ
routin
blood
test
blood
biochemistri
blood
ga
analysi
protein
procalcitonin
recommend
repeat
protein
procalcitonin
routin
blood
test
h
hospit
patient
order
differenti
treatment
failur
slow
respons
therapi
patient
sever
condit
monitor
ii
b
microbiolog
test
appropri
repeat
regular
microbiolog
test
molecular
biolog
serolog
assay
use
necessari
effort
made
obtain
etiolog
ii
b
chest
radiographi
recommend
repeat
chest
radiographi
regularli
patient
signific
improv
clinic
symptom
symptom
sign
persist
exacerb
chest
chest
ct
repeat
identifi
chang
lung
effect
initi
therapi
defin
situat
clinic
condit
patient
stabil
therapi
criteria
must
met
clinic
stabil
bodi
temperatur
heart
rate
bpm
respiratori
rate
bpm
system
blood
pressur
mm
hg
satur
arteri
partial
pressur
mm
hg
breath
air
ii
subsequ
manag
recommend
effect
initi
therapi
patient
signific
improv
symptom
initi
therapi
appropri
continu
treatment
patient
achiev
clinic
stabil
abl
receiv
oral
therapi
sequenti
therapi
administ
oral
prepar
type
antimicrobi
agent
anoth
agent
similar
antibacteri
fail
initi
therapi
defin
either
follow
situat
patient
symptom
improv
initi
therapi
requir
altern
antibiot
exacerb
diseas
progress
initi
improv
initi
therapi
ii
two
form
failur
primarili
observ
clinic
progress
pneumonia
diseas
progress
acut
respiratori
failur
requir
mechan
ventil
support
septic
shock
requir
vasoact
drug
therapi
within
h
arriv
unrespons
patient
achiev
clinic
stabil
h
initi
therapyloc
system
parapneumon
effus
empyema
ard
phlebiti
septicemia
metastat
abscess
risk
factor
failur
initi
therapi
potenti
factor
includ
nonbacteri
infect
bacteri
infect
cover
initi
treatment
noninfecti
diseas
see
flowchart
failur
initi
treatment
figur
discharg
consid
patient
clear
diagnosi
show
signific
improv
effect
treatment
evidenc
normal
bodi
temperatur
h
criteria
clinic
stabil
satisfi
moreov
patient
abl
receiv
oral
treatment
complic
disturb
conscious
requir
respiratori
tract
virus
play
import
role
adult
cap
direct
respons
pathogen
cap
facilit
onset
secondari
bacteri
pneumonia
due
pneumonia
aureu
primari
viral
pneumonia
secondari
concomit
bacteri
infect
virus
report
detect
chines
adult
cap
patient
normal
immun
common
virus
adult
cap
includ
influenza
viru
parainfluenza
viru
rhinoviru
adenoviru
hmpv
rsv
sinc
new
influenza
viru
becom
major
viral
strain
season
influenza
along
season
viral
strain
recent
year
also
case
pneumonia
caus
avian
influenza
viru
import
middl
east
respiratori
syndrom
mer
earli
diagnosi
base
epidemiolog
epidem
season
histori
travel
epidem
region
clinic
characterist
earli
antivir
therapi
within
h
onset
diseas
reason
support
therapi
critic
measur
reduc
ii
b
see
tabl
epidemiolog
clinic
characterist
treatment
viral
pneumonia
see
correspond
section
guidelin
inform
diagnosi
prophylaxi
epidemiolog
clue
especi
import
patient
highli
contagi
newli
discov
respiratori
tract
virus
china
legionella
pneumonia
account
legionella
pneumonia
usual
progress
sever
condit
almost
hospit
patient
due
legionella
infect
requir
icu
mortal
suscept
popul
includ
elderli
male
individu
chronic
underli
cardiac
pulmonari
diabet
malign
tumour
use
tumour
necrosi
relev
epidemiolog
histori
includ
contact
contamin
air
condition
air
condition
cool
tower
contamin
potabl
water
hot
recreat
spa
garden
activ
plumb
repair
histori
travel
area
legionella
possibl
legionella
pneumonia
suspect
adult
cap
patient
develop
follow
condit
fever
rel
bradycardia
acut
onset
headach
disturb
conscious
sleepi
diarrhoea
acut
renal
andor
hepat
impair
hyponatremia
hypophosphatemia
unrespons
rel
specif
manifest
legionella
pneumonia
chest
radiograph
sharpli
demarc
consolid
intermingl
opac
anoth
characterist
legionella
pneumonia
radiograph
progress
within
short
period
time
week
even
though
improv
clinic
symptom
may
take
sever
week
even
month
pulmonari
infiltr
complet
macrolid
respiratori
quinolon
doxycyclin
monotherapi
appropri
immunocompet
patient
mild
moder
legionella
pneumonia
quinolon
combin
rifampin
macrolid
recommend
patient
sever
condit
monotherapi
fail
immunocompromis
quinolon
combin
macrolid
physician
pay
close
attent
potenti
risk
abnorm
cardiac
current
pneumonia
rel
rare
mainland
china
small
number
case
report
children
similarli
among
skin
soft
tissu
infect
caus
aureu
mrsa
account
small
proport
among
pathogen
hospit
cap
patient
proport
mrsa
unit
state
accord
estim
incid
pneumonia
pneumonia
sever
diseas
associ
mortal
vulner
popul
includ
patient
individu
close
contact
mrsa
carrier
patient
individu
affect
influenza
viru
prison
profession
athlet
individu
serv
armi
recent
men
sex
men
intraven
drug
user
regular
sauna
user
use
antibacteri
agent
pneumonia
progress
rapidli
clinic
symptom
includ
fever
cough
chest
pain
gastrointestin
symptom
skin
rash
patient
seriou
condit
sever
pneumonia
symptom
hemoptysi
confus
ard
multipl
organ
failur
shock
may
appear
well
complic
acidosi
dissemin
intravascular
coagul
deep
vein
thrombosi
pneumothorax
empyema
pneumatocel
pulmonari
abscess
acut
necrot
radiograph
characterist
pneumonia
includ
extens
pulmonari
consolid
multipl
caviti
bilater
pneumonia
suspect
influenza
previous
healthi
young
patient
case
cavit
necrot
pneumonia
associ
rapid
increas
pleural
effus
massiv
hemoptysi
neutropenia
andor
erythemat
glycopeptid
linezolid
primari
choic
iii
b
current
consensu
definit
cap
elderli
elderli
cap
pneumonia
occur
popul
age
incid
elderli
cap
increas
age
clinic
manifest
elderli
cap
manifest
may
includ
poor
appetit
urinari
incontin
tired
alter
mental
state
typic
manifest
pneumonia
fever
cough
increas
wbcneutrophil
count
may
therefor
miss
diagnosi
misdiagnosi
may
occur
tachypnea
sensit
index
diagnosi
elderli
fever
atyp
symptom
appear
chest
radiographi
done
earli
possibl
confirm
pneumonia
still
main
pathogen
elderli
cap
possibl
enterobacteriacea
infect
consid
elderli
patient
underli
diseas
congest
heart
failur
cardiovascular
cerebrovascular
diseas
chronic
respiratori
system
diseas
renal
failur
diabet
mellitu
etc
patient
evalu
risk
factor
enterobacteriacea
empir
treatment
cephamycin
ertapenem
carbapenem
recommend
patient
high
risk
infect
enterobacteriacea
iii
b
relev
risk
factor
includ
histori
bacteri
colon
infect
prior
use
third
gener
cephalosporin
histori
repeat
hospit
indwel
medic
devic
renal
replac
elderli
patient
associ
reduc
organ
function
must
monitor
treatment
avoid
side
effect
reduc
renal
excret
may
caus
prolong
drug
dosag
reason
adjust
term
crcl
treat
ii
b
contraind
exist
hospit
elderli
cap
patient
evalu
risk
deep
vein
thrombosi
prophylaxi
low
molecular
weight
heparin
administ
ii
b
treatment
failur
rate
elderli
common
reason
concomit
sever
sepsi
myocardi
infarct
progress
cardiovascular
event
common
elderli
cap
one
reason
increas
aspir
pneumonia
pulmonari
infecti
lesion
caus
aspir
food
oropharyng
secret
gastric
content
throat
lower
respiratori
tract
includ
chemic
inflamm
lung
due
aspir
steril
gastric
major
case
aspir
pneumonia
caus
silent
aspir
account
around
elderli
follow
point
note
make
diagnosi
aspir
pneumonia
whether
risk
factor
aspir
eg
disturb
conscious
due
cerebrovascular
diseas
reason
dysphagia
periodont
diseas
poor
oral
hygien
whether
chest
radiograph
show
primari
lesion
posterior
segment
upper
lobe
dorsal
basal
segment
lower
lobe
hypostat
aspir
pneumonia
mostli
caus
infect
anaerob
bacteria
bacteria
aureu
treatment
cover
pathogen
base
sever
diseas
use
antimicrobi
agent
activ
acid
moxifloxacin
carbapenem
combin
metronidazol
clindamycin
ii
target
treatment
administ
result
sputum
cultur
antimicrobi
suscept
test
avail
intens
care
requir
elderli
patient
risk
factor
aspir
order
reduc
incid
aspir
pneumonia
specif
head
bed
elev
bedridden
patient
contraind
patient
appropri
posit
feed
patient
oral
hygien
maintain
reduc
bacteri
colon
oropharyng
area
elderli
patient
sever
dysphagia
alreadi
experienc
aspir
physician
evalu
risk
benefit
nasal
feed
via
indwel
gastric
tube
antipsychot
drug
antihistamin
anticholinerg
agent
avoid
ii
b
smoke
avoid
excess
alcohol
drink
adequ
nutrit
good
oral
help
prevent
pneumonia
iii
b
good
hand
hygien
habit
maintain
episod
respiratori
tract
symptom
cough
sneez
wear
mask
use
tissu
elbow
cloth
cover
nose
mouth
reduc
dissemin
respiratori
tract
iii
vaccin
pneumonia
reduc
risk
pneumonia
specif
popul
pneumonia
vaccin
current
use
includ
pneumococc
polysaccharid
vaccin
ppv
pneumococc
conjug
vaccin
pcv
china
pneumococc
polysaccharid
vaccin
market
effect
prevent
invas
pneumonia
recommend
follow
popul
b
age
year
age
year
chronic
pulmonari
diseas
chronic
cardiovascular
diseas
diabet
mellitu
chronic
renal
failur
nephrot
syndrom
chronic
hepat
diseas
includ
hepat
cirrhosi
alcohol
cochlear
implant
cerebrospin
fluid
leakag
immunodefici
function
organ
asplenia
resid
nurs
home
medic
institut
patient
one
dose
vaccin
intramuscular
subcutan
inject
recommend
usual
repeat
vaccin
advis
immunocompet
individu
although
appropri
individu
year
age
chronic
renal
failur
nephrot
syndrom
function
organ
asplenia
immunodefici
least
interv
two
dose
repeat
vaccin
necessari
individu
least
year
age
time
first
vaccin
b
pneumococc
conjug
vaccin
cover
pneumonia
serotyp
associ
excel
avail
china
market
vaccin
strategi
adult
age
year
receiv
pneumonia
vaccin
receiv
dose
dose
within
month
afterward
adult
age
year
receiv
one
dose
receiv
dose
least
one
year
latest
dose
adult
receiv
age
receiv
year
old
least
one
year
last
vaccin
repeat
vaccin
least
month
later
least
interv
two
dose
b
influenza
vaccin
prevent
influenza
reduc
also
protect
effect
influenza
pneumonia
bacteri
pneumonia
secondari
target
popul
influenza
vaccin
broader
pneumonia
vaccin
see
chines
guidelin
diagnosi
treatment
visit
websit
nation
influenza
detail
one
dose
influenza
vaccin
recommend
per
annual
influenza
combin
pneumococc
vaccin
influenza
vaccin
decreas
mortal
elderli
ii
b
bin
cao
speaker
invit
pfizer
gsk
bayer
qu
speaker
behalf
msd
china
pfizer
bayer
daiichi
sankyo
author
declar
conflict
interest
liu
contribut
advisor
author
contribut
critic
revis
final
approv
manuscript
concept
design
work
draft
section
qu
bin
cao
yi
huang
draft
section
cheng
draft
section
hui
wang
draft
section
hong
fan
yi
shi
draft
section
tian
zhang
draft
section
xu
draft
section
yu
chen
jing
zhang
draft
section
ning
shen
bei
contribut
methodolog
section
mei
jiang
ethic
approv
requir
